Policy shift favors one pivotal trial, aiming to cut costs, speed access and reshape how therapies for aging reach patients.
vist.ly/4sqrh
#longevity #FDA #DrugApproval #RegulatoryReform #BiotechPolicy #ClinicalDevelopment #AgingTherapeutics #HealthEconomics